Risk Factors, Prevalence, and Outcomes of Invasive Fungal Disease Post Cellular Therapies: A Real-World Analysis

Gavriilaki, Eleni; Dolgyras, Panagiotis; Dimou-Mpesikli, Sotiria; Poulopoulou, Aikaterini; Demosthenous, Christos; Zachrou, Evangelia; Siasios, Panagiotis; Mallouri, Despina; Vardi, Anna; Bousiou, Zoi; Panteliadou, Alkistis; Masmanidou, Marianna; Lalayanni, Chrysavgi; Yannaki, Evangelia; Sotiropoulos, Damianos; Anagnostopoulos, Αchilles; Vyzantiadis, Timoleon; Sakellari, Ioanna

doi:10.1182/blood-2022-156570

Search citation statements

Order By: Relevance

Paper Sections

Select...

Bridging the Lab To Clinical Practice: Fda Approvals And Cli...1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the case of B cell lymphoid pathologies, CART anti-CD19 cells cause an aplasia in this line, leading to a break in the humoral immune system and, consequently, hypogammaglobulinemia. This condition increases the risk of infection due to reduced levels of antibodies but can be resolved through intravenous immunoglobulin supplementation and antiviral, antibacterial, and antifungal prophylaxis (36,37), although an increase in fungal infection has not been documented in these patients (38).…”

Section: Bridging the Lab To Clinical Practice: Fda Approvals And Cli...mentioning

confidence: 99%

Mini review: Advances and challenges in CAR-T cell therapy: from early chimeric antigen receptors to future frontiers in oncology

Ceballos,

Viguria,

Panizo

et al. 2023

Front. Hematol.

View full text Add to dashboard Cite

Cell therapy utilizing chimeric antigen receptors (CARs) in conjunction with immune cells, primarily T lymphocytes, is known as CAR-T cell therapy. This innovative approach is revolutionizing the landscape of oncohaematology by precisely targeting specific antigens for elimination. However, despite its promising prospects, CAR-T therapy presents several challenges, including a notable rate of disease relapse, intricate pathologies impeding widespread adoption, prolonged manufacturing timelines, and substantial costs. Looking forward, ongoing research and progress aim to address these challenges to mitigate these constraints, underlining the continuous efforts to enhance the efficacy and accessibility of this transformative therapy

show abstract

Section: Bridging the Lab To Clinical Practice: Fda Approvals And Cli...mentioning

confidence: 99%

Mini review: Advances and challenges in CAR-T cell therapy: from early chimeric antigen receptors to future frontiers in oncology

Ceballos,

Viguria,

Panizo

et al. 2023

Front. Hematol.

View full text Add to dashboard Cite

show abstract

Risk Factors, Prevalence, and Outcomes of Invasive Fungal Disease Post Cellular Therapies: A Real-World Analysis

Cited by 1 publication

References 0 publications

Mini review: Advances and challenges in CAR-T cell therapy: from early chimeric antigen receptors to future frontiers in oncology

Mini review: Advances and challenges in CAR-T cell therapy: from early chimeric antigen receptors to future frontiers in oncology

Contact Info

Product

Resources

About